However, according to a study by Han et al. (2017), high expression levels of miR-222 in patients with ER+ breast cancer were significantly (P = 0.021) associated with decreased disease-free survival as compared to ER+ breast cancer patients exhibiting low levels of miR-222 [31]. The gene discussed is ESR1; the disease is breast carcinoma.